Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy
| Study Type |
Interventional (Clinical Trial) |
| Sponsor Name |
Abbvie |
| Disease type |
Small Cell Lung Cancer |
| Disease Stage |
IV |
| Clinical Status |
Second Line |
| Phase |
III |
| Intervention / Treatment |
Rovalpituzumab Teserine / Topotecan |
| Research Site |
Sacré Coeur |
| Investigator |
Dr Kevin Jao |
| Coordinator |
Anne-Marie Laliberté |
| Telephone number |
|
| Fax number |
|
| Study start date |
23-Feb-17 |
| Study end date |
– |
| Trial Status |
Recruiting |
| Study Type |
Treatment, Clinical Research |
| Sponsor Name |
|
| Tumor Site |
Small Cell Lung Cancer |
| Disease Stage |
Stage IV |
| Clinical Status |
|
| Phase |
Phase I |
| Intervention / Treatment |
|
| Research Site |
Montreal, QC |
| Investigator |
|
| Coordinator |
|
| Telephone Number |
514-338-2222 ext 2818 |
| Fax Number |
|
| Study Start Date |
|
| Study End Date |
|
| Trial Status |
|
Tags
